 |
|
Increased Incidence of Infectious Diseases During Prospective Follow-up of Human T-Lymphotropic Virus Type II– and I–Infected Blood Donors
Edward L. Murphy, MD, MPH;
Simone A. Glynn, MD, MPH;
Joy Fridey, MD;
James W. Smith, MD, PhD;
Ronald A. Sacher, MD;
Catharie C. Nass, PhD;
Helen E. Ownby, PhD;
David J. Wright, PhD;
George J. Nemo, PhD;
for the Retrovirus Epidemiology Donor Study
Arch Intern Med. 1999;159:1485-1491.
Background To determine whether human T-lymphotropic virus type II (HTLV-II) infection is associated with an increased incidence of bacterial infections, we prospectively observed cohorts of HTLV-I– and HTLV-II–infected and seronegative subjects in 5 US cities.
Methods Of 1340 present and former blood donors examined at enrollment, 1213 (90.5%) were re-examined after approximately 2 years, including 136 HTLV-I– and 337 HTLV-II–seropositive subjects and 740 demographically stratified HTLV-seronegative subjects. All subjects were seronegative for human immunodeficiency virus. Odds ratios (ORs) for incident disease outcomes were adjusted for covariates, including age, sex, race or ethnicity, education, and, if significantly associated with the outcome, blood center, donation type, income, smoking, alcohol intake, and injected drug use.
Results Compared with seronegative status, HTLV-II infection was associated with an increased incidence of bronchitis (OR, 1.81; 95% confidence interval [CI], 1.20-2.75), bladder and/or kidney infection (OR, 1.94; 95% CI, 1.26-2.98), oral herpes infection (OR, 9.54; 95% CI, 3.33-27.32), and a borderline increased incidence of pneumonia (OR, 2.09; 95% CI, 0.92-4.76); HTLV-I infection was associated with an increased incidence of bladder and/or kidney infection (OR, 2.79; 95% CI, 1.63-4.79). One incident case of HTLV-I–positive adult T-cell leukemia was observed (incidence, 348 per 100,000 HTLV-I person-years), and 1 case of HTLV-II–positive tropical spastic paraparesis–HTLV-associated myelopathy was diagnosed (incidence, 140 per 100,000 HTLV-II person-years).
Conclusions These data support an increased incidence of infectious diseases among otherwise healthy HTLV-II– and HTLV-I–infected subjects. They are also consistent with the lymphoproliferative effects of HTLV-I, and with neuropathic effects of HTLV-I and HTLV-II.
From the Department of Laboratory Medicine, University of California, San Francisco (Dr Murphy); Westat Inc, Rockville, Md (Drs Glynn and Wright); the Blood Bank of San Bernardino County, San Bernadino, Calif (Dr Fridey); the Oklahoma Blood Institute, Oklahoma City (Dr Smith); Department of Laboratory Medicine, Georgetown University Hospital, Washington, DC (Dr Sacher); American Red Cross Blood Services–Chesapeake Region, Baltimore, Md (Dr Nass); American Red Cross Blood Services–Southeastern Michigan, Detroit (Dr Ownby); and the National Heart, Lung and Blood Institute, Bethesda, Md (Dr Nemo). Participants from the Retrovirus Epidemiology Donor Study are listed below.
RELATED ARTICLE
Archives of Internal Medicine Reader's Choice: Continuing Medical Education
Arch Intern Med. 1999;159(13):1503.
FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Hematologic hints of HTLV-2 in US blood donors
Beilke
Blood 2008;112:3919-3920.
FULL TEXT
Long-term increases in lymphocytes and platelets in human T-lymphotropic virus type II infection
Bartman et al.
Blood 2008;112:3995-4002.
ABSTRACT
| FULL TEXT
Prevalence and clinical features of HTLV neurologic disease in the HTLV Outcomes Study
Orland et al.
Neurology 2003;61:1588-1594.
ABSTRACT
| FULL TEXT
A Cohort Study of Health Effects of Human T-Cell Lymphotropic Virus Type I Infection in Jamaican Children
Maloney et al.
Pediatrics 2003;112:e136-142.
ABSTRACT
| FULL TEXT
ASSOCIATION AND EPIDEMIOLOGIC FEATURES OF TRYPANOSOMA CRUZI AND HUMAN T CELL LYMPHOTROPIC A VIRUS TYPE II IN INHABITANTS OF THE PARAGUAYAN GRAN CHACO
FERRER et al.
Am J Trop Med Hyg 2003;68:235-241.
ABSTRACT
| FULL TEXT
|
